Mont-Saint-Guibert, Belgium - Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a pioneer in the discovery and development of CAR-T cell therapies, organized a call today to provide an update on Celyad's clinical strategy. Christian Homsy, Chief Executive Officer, and Patrick Jeanmart, Chief Financial Officer, delivered a brief presentation followed by a Q&A session.

Click here to listen to the conference call

Celyad SA published this content on 06 October 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 06 October 2017 15:49:03 UTC.

Original documenthttps://www.celyad.com/en/news/conference-call-update-on-clinical-strategy

Public permalinkhttp://www.publicnow.com/view/C22A0EDBEDF1029E4CE2B5AB960B1FA91E237FCE